市场调查报告书

全球恒温核酸增幅技术(INAAT)市场:各技术、用途、地区 - 成长,趋势,预测(2018年~2023年)

Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market - Segmented by Technology, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品编码 390904
出版日期 内容资讯 英文 112 Pages
商品交期: 2-3个工作天内
价格
全球恒温核酸增幅技术(INAAT)市场:各技术、用途、地区 - 成长,趋势,预测(2018年~2023年) Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market - Segmented by Technology, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日期: 2018年05月01日内容资讯: 英文 112 Pages
简介

全球恒温核酸增幅技术(INAAT)市场,预计从2018年到2023年的预测期间记录10.5%的年复合成长率。

本报告提供全球恒温核酸增幅技术(INAAT)市场调查,市场概要,各技术、用途、地区的市场规模的变化与预测,市场成长要素、阻碍因素以及市场机会、课题分析,竞争情形,主要企业的简介等全面性资讯。

目录

第1章 简介

  • 市场定义

第2章 调查方法

第3章 摘要整理

第4章 主要影响要素

第5章 市场概要

  • 目前市场方案
  • 波特的五力分析
    • 买方议价能力
    • 供给企业谈判力
    • 新加入业者的威胁
    • 替代品的威胁
    • 竞争企业间的敌对关系

第6章 成长要素,阻碍因素,机会,课题分析(DROC)

  • 市场成长要素
    • 分子诊断的剧增
    • 慢性疾病的罹患率的上升和高龄化
    • 与PCR(聚合酶链反应法)比较,INAAT的采用增加
  • 市场阻碍因素
    • PCR技术的威胁
    • 新诊断技术的认知度不足
  • 市场机会
  • 主要课题

第7章 市场区隔

  • 各技术
    • HDA法
    • NEAR法
    • LAMP法
    • SDA法
    • NASBA法
    • TMA法
    • SPIA法
    • 其他
  • 各用途
    • 肿瘤
    • 研究调查
    • 诊断
    • 血液筛检
    • 其他
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东、非洲
    • 南美

第8章 竞争情形

  • M&A分析
  • 协定,合作,伙伴关系
  • 新产品的销售

第9章 主要企业

  • Alere, Inc.
  • Becton, Dickinson & Company
  • BioHelix
  • bioMerieux
  • Hologica
  • New England Biolabs
  • Nugen
  • Qiagen
  • Quidel Corporation
  • 清单未完全网罗

第10章 市场未来展望

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 49281

The global isothermal nucleic acid amplification technology (INAAT) market is expected to register a CAGR of 10.5%, during the forecast period, (2018-2023). North America dominates the market, due to technological advancement and growing awareness regarding INAAT technique among end-user in the region.

Rise in the Miniaturization of Nucleic Acid based Diagnostics

Miniaturization of biochemical reactions leads to major advantages, where a lower amount of valuable clinical sample and reagents is just one: approximately 1/1000 of the volume used in conventional lab setups has been shown to obtain a similar result. A smaller heat capacity allows for rapid changes in temperature beneficial for the PCR time, as well as a higher parallelism of multiple genetic samples. The benefit of isothermal amplification methods compared to PCR is the constant temperature of amplification. This will result in a high potential for a simple integration in point-of-care devices and a reduction of complexity. With increasing demand of low cost and effective solutions for diagnosis of diseases and increasing demand for point of care applications, these devices are going to witness growth in the future. Also in case of laboratories the sample size required is very small which also helps in reducing the amount of reagents required. Also, the upsurge in the molecular diagnostics market, increasing incidences of chronic diseases and aging population, and increase in the adoption of INAAT over PCR are driving the market growth.

Stringent regulatory framework

In the expanding market for medical devices and therapies, there are stringent regulatory policies in place to ensure the safety of such drugs and devices. These policies are well studied. However, while rigorous regulatory procedures guarantee the quality of the product entering the market, they delay the entry of a drug or device into the market, which could be beneficial to all patients suffering from a disease. Pre-market approval is an FDA process of scientific and regulatory review to evaluate the safety and effectiveness of drugs and devices. There have been procedures by the FDA to heighten the post-market surveillance. The FDA review process takes twice as much as time as European regulatory commissions review bodies. Hence, citizens from countries where the review process is shorter benefit more than countries with longer review processes and stringent regulations. The presence of stringent regulations is dampening the innovation in the market and hindering the growth of this market. Strict regulatory policies have resulted in a reduction of investment by drug companies in R&D of new products. Also the lack of awareness in new diagnostics technologies may induce users to stick to conventional methods, although this can be addressed with effective marketing

North America to Dominate the Market

North America dominates the Isothermal Nucleic Acid Amplification Technology (INAAT) market, owing to high incidence of chronic diseases, technological advancement in isothermal nucleic acid amplification technology (INAAT), and increasing adoption of INAAT over conventional techniques in the region. Asia Pacific is expected to grow during the forecast period, owing to factors, such as high demand in cost effective and diagnostics, less stringent regulatory scenario, and presence of huge population base.

Key Developments in the Market

March 2017: Alere Inc. a global leader in rapid diagnostic tests, announced that the U.S. Food and Drug Administration (FDA) has granted CLIA waiver for the Alere i Strep A test

Major Players: ALERE, BECTON, DICKINSON & COMPANY, BIOMERIUX, HOLOGICA, LUCIGEN, QUIDEL CORPORATION, NEW ENGLAND BIOLABS, NUGEN, QIAGEN, USTAR BIOTECHNOLOGIES, amongst others.

Reasons to Purchase this Report

Current and future global isothermal nucleic acid amplification technology outlook, in the developed and emerging markets

Analysis of various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness the fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3 months analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Upsurge in the Molecular Diagnosis
    • 6.1.2 Increasing Incidences of Chronic Diseases and Aging Population
    • 6.1.3 Increase in the Adoption of INAAT over PCR
    • 6.1.4 Rise in the Miniaturization of Nucleic Acid Based Diagnosis
  • 6.2 Market Restraints
    • 6.2.1 Threatening Opposition from PCR Technologies
    • 6.2.2 Lack of Awareness of New Diagnostics Technologies
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Technology
    • 7.1.1 Helicase-dependent Amplification (HDA)
    • 7.1.2 Nicking Enzyme Amplification Reaction (NEAR)
    • 7.1.3 Loop-mediated Isothermal Amplification (LAMP)
    • 7.1.4 Strand Displacement Amplification (SDA)
    • 7.1.5 Nucleic Acid Sequence Based Amplification (NASBA)
    • 7.1.6 Transcription Mediated Amplification (TMA)
    • 7.1.7 Single Primer Isothermal Amplification (SPIA)
    • 7.1.8 Others
  • 7.2 By Applications
    • 7.2.1 Oncology
    • 7.2.2 Laboratory Research
    • 7.2.3 Diagnostics
    • 7.2.4 Blood Screening
    • 7.2.5 Others
  • 7.3 By Geography
    • 7.3.1 North America
      • 7.3.1.1 United States
      • 7.3.1.2 Canada
      • 7.3.1.3 Mexico
    • 7.3.2 Europe
      • 7.3.2.1 France
      • 7.3.2.2 Germany
      • 7.3.2.3 United Kingdom
      • 7.3.2.4 Italy
      • 7.3.2.5 Spain
      • 7.3.2.6 Rest Of Europe
    • 7.3.3 Asia-Pacific
      • 7.3.3.1 China
      • 7.3.3.2 Japan
      • 7.3.3.3 India
      • 7.3.3.4 Australia & New Zealand
      • 7.3.3.5 South Korea
      • 7.3.3.6 Rest of Asia-Pacific
    • 7.3.4 Middle East & Africa
      • 7.3.4.1 GCC
      • 7.3.4.2 South Africa
      • 7.3.4.3 Rest of the Middle East & Africa
    • 7.3.5 South America
      • 7.3.5.1 Brazil
      • 7.3.5.2 Argentina
      • 7.3.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Alere, Inc.
  • 9.2 Becton, Dickinson & Company
  • 9.3 BioHelix
  • 9.4 bioMerieux
  • 9.5 Hologica
  • 9.6 New England Biolabs
  • 9.7 Nugen
  • 9.8 Qiagen
  • 9.9 Quidel Corporation
  • 9.10 List Not Exhaustive

10. Future of the Market